DCB Newsletter #11: Looking back – our milestones in 2022

by Greta | Dec 20, 2022 | Linkedin

DCB Newsletter #11: Looking back – our milestones in 2022

Dear DCB community,

The year 2022 is almost history and we take this opportunity to look back on 2022 – the fifth year of the existence of DCB. A lot has been going on! But see for yourself:

Quality & HR

We have continued to grow – all open positions were successfully filled, that means 9 new team members were recruited in 2022.
We implemented a document management system. Also, we implemented and certified the relevant processes for the DCB Management System according to ISO 9001. The audit went great and they reported zero findings!

Innovation & Business Development

Oh yes, we did innovate and develop our business in 2022! The team evaluated >200 ideas, proposals, and applications. Several dozen projects/startups were supported by DCB: With expertise, access to our network, facilities, and funding.
The DCB Open Innovation Challenge was again a huge success! 66 applications from 22 different countries helped grow the vibrant DiabetesTech community and resulted in the six final projects from Denmark, France, Australia, Germany and the U.S. Our highlight, the DCB Start-Up Night & Award Ceremony took place on 30 November, where the jury selected the two winners: Ole Kjerkegaard Nielsen with GO-Pen ApS from Denmark (Category Diabetes Devices) and Pascal Grimm with Una Health from Germany (Category Digital Diabetes).

Clinical & Data

First clinical study terminated: Our first clinical study has been conducted at the Universitätsklinik für Diabetologie, Endokrinologie, Ernährungsmedizin& Metabolismus (UDEM), Berne, Switzerland and Institut für Diabetes-Technologie (IfDT), Ulm, Germany. For this study, for an insulin pump manufacturer, we were responsible for the whole clinical process from clinical study plan writing, EC submission, material supply, site monitoring, data cleaning and analyzing to the study report writing.
The secure web-based EDC system, REDCap, deployed: With the support of iSolutions and the IT department of the Institute of Social and Preventive Medicine of the University of Bern, REDCap, a secure web-based EDC system, has been deployed into a Cloud Environment (PaaS). DCB will use REDCap for the collection of data from various clinical trials and medical registries.
Clinical / Data teams grew: Five new employees, Stefanie Hossmann, Constance Bischoff, Dr. Stefanie Hofer, Dominique Rubi and Aritz Lizoain joined DCB and brought their expertise, experience and good mood to the Clinical and Data Teams.
3 internships successfully finished:

Laura Burlando conducted a systematic review on the effect of the menstrual cycle on diabetes management for her master’s in eHealth at the University of Lucerne.

Aritz Lizoain performed data analysis of in-vitro glucose measurements and contributed to the development of a continuous glucose monitoring sensor to complete his master’s in statistics at the University of Neuchâtel.

Katja Kilcher did a qualitative research project with regards to global regulations and requirements for electronic Consent processes.

FibreGum starts for recruitment: The clinical study FibreGum, under the supervising of Prof. Maria Luisa Balmer, started for recruitment at the Children Clinic Berne. The study will assess the effect of an additive in a chewing gum on body weight loss. 105 adolescents and young adults, treated at the weight management department, will be included over 2 years.

Associated research group of Prof. Dr. phil. Lilian Witthauer

The samlab (sensing & monitoring lab) has successful initiated the moonwalk pilot study where they investigate the relationship beween nocturnal hypogycemia symptoms and sleep
The samlab has built up their optical lab and in now ready to perform cutting edge research

Thank you, dear readers for your loyalty and interest throughout the year! We will continue to provide you with new series, inside stories and regular updates in 2023. All the best and till soon!?



This post was previously published in Linkedin. Click here to see the original publication.

More recent news

DCB Newsletter #3/24: The DCB Open Innovation Challenge is back!

19 · Apr · 2024 | Linkedin

Dear community, it's that time of the year again...the DCB Open Innovation Challenge is back – and this time, it's...

DCB Newsletter #2/24: DID YOU KNOW… you can help crowdfund innovative diabetes education for South Africans?

3 · Apr · 2024 | Linkedin

Dear Community, we are happy to present you with the next episode of our series “DID YOU KNOW” – this time, with a...

DCB Newsletter #1/24: DID YOU KNOW… that there are Rare Types of Diabetes?

3 · Apr · 2024 | Linkedin

Dear Community, we are happy to present you with the next episode of our series “DID YOU KNOW” in which we publish...

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

info@dcberne.com

Legal notice

Data Protection Statement

DCB Open Innovation Challenge: GO-Pen and Una Health emerge as winners of 2022

by Greta | Dec 1, 2022 | Innovation

Back to News

DCB Open Innovation Challenge: GO-Pen and Una Health emerge as winners of 2022

On November 30, this year’s DCB Start-Up Night and Award Ceremony of the Open Innovation Challenge 2022 took place. After an exciting evening of pitching, an international jury chose the winners of the second edition of the Innovation Challenge, which this year was split up into the two categories “Diabetes Devices” starting in spring, and “Digital Diabetes” starting in summer.

66 ideas from 22 countries were submitted to the Challenge, with three finalists in each category. These six finalists from the U.S, Denmark, France, Australia, and Germany pitched their projects live on stage in Bern in front of a hundred guests and a large fan community watching online. The first prizes of each 100.000 USD in funding and in-kind support went to GO-Pen (Denmark) in the category Diabetes Devices and to Una Health (Germany) in the category Digital Diabetes.

Simon Michel (Board Member DCB), Derek Brandt (CEO DCB) and Ole Kjerkegaard Nielsen (CEO Go-Pen)

GO-Pen is developing an affordable, reliable and sustainable insulin pen. Their vision is to make a difference for the millions of people living with diabetes who currently cannot afford modern devices. Derek Brandt, CEO of Diabetes Center Berne said:

“The innovation, the need in the market and the business model convinced the jury in their decision. GO-Pen has clearly defined target markets. For example, about 4 million people in the USA still use standard syringes for injecting insulin every day. This is exactly where GO-Pen wants to come in with its solution and provide those affected with a solution that allows for a simpler and more precise dosage of insulin, but hardly increases the costs compared to a conventional syringe. This solution can also provide significant added value for people with diabetes in low and middle income countries. Especially in these regions, the number of people affected is rapidly increasing.”

Pascal Grimm (CEO Una Health) and Dr. Katarina Braune (Jury Member)

Una Health, winner of the category Digital Diabetes, enables people with type 2 diabetes to understand what is driving their condition and to make simple, targeted changes to improve their health sustainably. For this, biosensor and lifestyle data are combined with behavioral science-based change models in a user centered certified mobile app.

“What has caused my blood sugar to spike? This is a question that people with type 2 diabetes frequently ask themselves. That’s where Una Health comes in and has developed an approach in which people with type 2 diabetes learn via an app and the use of continuous glucose sensors how food and their behaviour affect their blood glucose; this with the aim of improving blood glucose in the long term. The goal is clear: control over blood sugar also means more control over the quality of life of the person affected. The jury is convinced that continuous learning and understanding of the correlations will sustainably improve the long-term prognosis of people with diabetes and in this case type 2 diabetes.”

said Derek Brandt.

The two winners were awarded with 100.000 USD each, consisting of 60.000 USD in funding and 40.000 USD in in-kind support (services provided by DCB and its partner network). The four remaining finalists received 20.000 USD each, consisting of 10.000 USD in funding and 10.000 USD in in-kind support:

Diabetes Devices

BOYDSense (Germany): BOYDSense gives people access to gentle, non-invasive health monitoring starting with diabetes. They leverage molecules (volatile organic compounds) present in exhaled breath correlated with glucose biomarkers to accurately calculate the glucose value in real-time and a very user-friendly way.

Diatech Diabetes (U.S.): SmartFusion is an infusion monitoring platform for people with insulin pumps and automated insulin delivery devices. Their technology works by analyzing historical and real-time data from insulin pumps + continuous glucose monitors to better detect the occurrence of infusion set failure and reduce severe hyperglycemia from insulin dosing.

Digital Diabetes

Balance Health (Australia): Balance Health is taking patient engagement and centricity to the next level. A level where the clinician and the patient can collaborate to determine what CGM alerts the patient would like to receive and how often. This proprietary knowledge acquisition approach that they are developing means that a patient will feel like they have their clinician checking their CGM data daily and messaging them if there is something worthwhile to share.

EkiYou (France): What if people with diabetes had in their pocket: A super calculator for insulin doses, access to dieticians/nurses to ask questions and access to a community of patients to share their experience? They would increase their time in range, would feel less anxious about their disease and would personalise their treatment in an autonomous way.

About the DCB Open Innovation Challenge

After the initial launch in 2021, the DCB Open Innovation Challenge took place for the second time this year. The aim of the Challenge is to promote innovative, international projects in the field of diabetes management. With a total prize money of 280.000 USD, the DCB Open Innovation Challenge is one of the world’s most generous international awards in the area of diabetes. Applications are open to start-ups, medical and research professionals, and individuals.